|
DANIEL M. MILLER
Partner
(604) 630-5199
FAX (604) 687-8504
miller.dan@dorsey.com
|
August 15, 2013
|
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549-7010
USA
|
| Attention: | Mr. Jeffrey P. Riedler
Assistant Director
|
| Re: | Tekmira Pharmaceuticals Corporation
Form 20-F Annual Report
Filed March 27, 2013
File No. 001-34949
|
Dear Sirs and Mesdames:
On behalf of our client, Tekmira Pharmaceuticals Corporation (the “Company”), and pursuant to the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, reference is made to the Staff’s letter to the Company, dated August 8, 2013 (the “Comment Letter”), in respect of the above noted filings.
In order to respond to the Comment Letter, it is necessary for the Company to first consult with certain of the counterparties to the agreements referenced in the comment contained in the Comment Letter. Therefore, as a result of the time that it will take to make such consultations, the Company currently expects that it will be in a position to respond to the comment contained in the Comment Letter on or before September 6, 2013.
If you should have any questions or concerns regarding the anticipated timing of our response, please do not hesitate to contact me at (604) 630-5199.
| Yours truly, | |
| /s/ Daniel M. Miller | |
| Daniel M. Miller |
| cc: |
Ian Mortimer
Tekmira Pharmaceuticals Corporation.
|
